ImmuCell Historical Balance Sheet

ICCC Stock

USD 5.35 0.13 2.37%

Trend analysis of ImmuCell balance sheet accounts such as Other Current Liabilities of 1.5 M or Total Current Liabilities of 5.1 M provides information on ImmuCell's total assets, liabilities, and equity, which is the actual value of ImmuCell to its prevalent stockholders. By breaking down trends over time using ImmuCell balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining ImmuCell latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ImmuCell is a good buy for the upcoming year.

ImmuCell Inventory

9.43 Million

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuCell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.

About ImmuCell Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of ImmuCell at a specified time, usually calculated after every quarter, six months, or one year. ImmuCell Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of ImmuCell and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which ImmuCell currently owns. An asset can also be divided into two categories, current and non-current.

ImmuCell Balance Sheet Chart

At present, ImmuCell's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 1.5 M, whereas Retained Earnings are projected to grow to (13.1 M).

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of ImmuCell assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in ImmuCell books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on ImmuCell balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of ImmuCell are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from ImmuCell's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into ImmuCell current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuCell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.At present, ImmuCell's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 1.5 M, whereas Retained Earnings are projected to grow to (13.1 M).

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	12.5M	16.7M	19.2M	20.2M
Total Assets	44.9M	43.8M	50.4M	52.9M

Short Long Term Debt Total Total Assets

ImmuCell balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Property Plant And Equipment Gross	Common Stock Total Equity	Common Stock
Total Assets		0.95	0.88	0.92	0.97	0.99	0.72	-0.7	0.41	0.99	-0.02	0.01	0.96	0.98	0.95	0.8	-0.29	0.99	0.95	0.65	0.86	0.28	0.66	0.96	0.85	0.88
Short Long Term Debt Total	0.95		0.95	0.97	0.84	0.96	0.9	-0.86	0.11	0.96	0.11	-0.29	0.91	0.96	0.99	0.92	-0.2	0.95	1.0	0.44	0.93	0.1	0.57	0.97	0.74	0.78
Other Current Liab	0.88	0.95		0.94	0.76	0.88	0.89	-0.93	0.03	0.88	0.28	-0.33	0.86	0.92	0.94	0.95	-0.06	0.92	0.95	0.43	0.89	-0.05	0.49	0.96	0.66	0.72
Total Current Liabilities	0.92	0.97	0.94		0.82	0.93	0.89	-0.86	0.07	0.93	0.13	-0.27	0.9	0.94	0.96	0.94	-0.17	0.94	0.98	0.47	0.92	0.15	0.67	0.95	0.71	0.75
Total Stockholder Equity	0.97	0.84	0.76	0.82		0.94	0.54	-0.54	0.6	0.94	-0.12	0.22	0.93	0.94	0.86	0.66	-0.34	0.94	0.85	0.74	0.75	0.37	0.65	0.89	0.88	0.9
Property Plant And Equipment Net	0.99	0.96	0.88	0.93	0.94		0.77	-0.72	0.32	1.0	0.01	-0.12	0.93	0.97	0.97	0.8	-0.25	0.97	0.96	0.53	0.88	0.29	0.63	0.97	0.83	0.86
Net Debt	0.72	0.9	0.89	0.89	0.54	0.77		-0.89	-0.34	0.77	0.23	-0.63	0.69	0.75	0.87	0.92	-0.08	0.74	0.9	0.09	0.85	-0.11	0.44	0.82	0.45	0.5
Retained Earnings	-0.7	-0.86	-0.93	-0.86	-0.54	-0.72	-0.89		0.18	-0.71	-0.38	0.52	-0.72	-0.78	-0.83	-0.93	-0.12	-0.79	-0.85	-0.25	-0.86	0.2	-0.33	-0.82	-0.51	-0.57
Cash	0.41	0.11	0.03	0.07	0.6	0.32	-0.34	0.18		0.32	-0.28	0.81	0.4	0.36	0.15	-0.13	-0.23	0.37	0.12	0.74	0.07	0.47	0.22	0.23	0.57	0.54
Non Current Assets Total	0.99	0.96	0.88	0.93	0.94	1.0	0.77	-0.71	0.32		-0.01	-0.12	0.93	0.97	0.97	0.8	-0.27	0.97	0.96	0.53	0.88	0.27	0.62	0.97	0.83	0.85
Non Currrent Assets Other	-0.02	0.11	0.28	0.13	-0.12	0.01	0.23	-0.38	-0.28	-0.01		-0.42	-0.06	0.04	0.1	0.24	0.66	0.06	0.11	-0.12	0.2	-0.06	-0.12	0.12	-0.04	0.0
Cash And Short Term Investments	0.01	-0.29	-0.33	-0.27	0.22	-0.12	-0.63	0.52	0.81	-0.12	-0.42		0.01	-0.03	-0.25	-0.4	-0.34	-0.04	-0.27	0.63	-0.33	0.31	0.09	-0.18	0.19	0.15
Net Receivables	0.96	0.91	0.86	0.9	0.93	0.93	0.69	-0.72	0.4	0.93	-0.06	0.01		0.96	0.91	0.78	-0.27	0.96	0.91	0.63	0.83	0.18	0.62	0.94	0.8	0.83
Common Stock Shares Outstanding	0.98	0.96	0.92	0.94	0.94	0.97	0.75	-0.78	0.36	0.97	0.04	-0.03	0.96		0.95	0.85	-0.26	1.0	0.96	0.63	0.89	0.15	0.57	0.97	0.83	0.86
Non Current Liabilities Total	0.95	0.99	0.94	0.96	0.86	0.97	0.87	-0.83	0.15	0.97	0.1	-0.25	0.91	0.95		0.89	-0.2	0.96	0.99	0.49	0.91	0.14	0.59	0.98	0.79	0.83
Inventory	0.8	0.92	0.95	0.94	0.66	0.8	0.92	-0.93	-0.13	0.8	0.24	-0.4	0.78	0.85	0.89		-0.13	0.85	0.92	0.37	0.87	-0.13	0.52	0.89	0.56	0.62
Other Current Assets	-0.29	-0.2	-0.06	-0.17	-0.34	-0.25	-0.08	-0.12	-0.23	-0.27	0.66	-0.34	-0.27	-0.26	-0.2	-0.13		-0.21	-0.19	-0.28	-0.14	0.2	-0.09	-0.18	-0.2	-0.19
Other Stockholder Equity	0.99	0.95	0.92	0.94	0.94	0.97	0.74	-0.79	0.37	0.97	0.06	-0.04	0.96	1.0	0.96	0.85	-0.21		0.96	0.64	0.89	0.2	0.61	0.98	0.83	0.87
Total Liab	0.95	1.0	0.95	0.98	0.85	0.96	0.9	-0.85	0.12	0.96	0.11	-0.27	0.91	0.96	0.99	0.92	-0.19	0.96		0.46	0.92	0.12	0.61	0.98	0.74	0.78
Total Current Assets	0.65	0.44	0.43	0.47	0.74	0.53	0.09	-0.25	0.74	0.53	-0.12	0.63	0.63	0.63	0.49	0.37	-0.28	0.64	0.46		0.4	0.28	0.5	0.54	0.8	0.8
Short Term Debt	0.86	0.93	0.89	0.92	0.75	0.88	0.85	-0.86	0.07	0.88	0.2	-0.33	0.83	0.89	0.91	0.87	-0.14	0.89	0.92	0.4		0.05	0.4	0.89	0.72	0.76
Intangible Assets	0.28	0.1	-0.05	0.15	0.37	0.29	-0.11	0.2	0.47	0.27	-0.06	0.31	0.18	0.15	0.14	-0.13	0.2	0.2	0.12	0.28	0.05		0.62	0.13	0.38	0.33
Accounts Payable	0.66	0.57	0.49	0.67	0.65	0.63	0.44	-0.33	0.22	0.62	-0.12	0.09	0.62	0.57	0.59	0.52	-0.09	0.61	0.61	0.5	0.4	0.62		0.59	0.53	0.54
Property Plant And Equipment Gross	0.96	0.97	0.96	0.95	0.89	0.97	0.82	-0.82	0.23	0.97	0.12	-0.18	0.94	0.97	0.98	0.89	-0.18	0.98	0.98	0.54	0.89	0.13	0.59		0.78	0.83
Common Stock Total Equity	0.85	0.74	0.66	0.71	0.88	0.83	0.45	-0.51	0.57	0.83	-0.04	0.19	0.8	0.83	0.79	0.56	-0.2	0.83	0.74	0.8	0.72	0.38	0.53	0.78		1.0
Common Stock	0.88	0.78	0.72	0.75	0.9	0.86	0.5	-0.57	0.54	0.85	0.0	0.15	0.83	0.86	0.83	0.62	-0.19	0.87	0.78	0.8	0.76	0.33	0.54	0.83	1.0

Click cells to compare fundamentals

ImmuCell Account Relationship Matchups

ImmuCell balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	40.4M	44.5M	44.9M	43.8M	50.4M	52.9M
Short Long Term Debt Total	10.7M	10.3M	12.5M	16.7M	19.2M	20.2M
Other Current Liab	747.9K	867.1K	1.2M	1.2M	1.4M	1.5M
Total Current Liabilities	2.2M	2.5M	3.1M	4.2M	4.8M	5.1M
Total Stockholder Equity	28.3M	32.6M	30.4M	25.0M	28.7M	30.2M
Property Plant And Equipment Net	28.0M	28.0M	30.6M	32.1M	37.0M	38.8M
Net Debt	2.8M	89.0K	6.7M	15.7M	18.1M	19.0M
Retained Earnings	(3.7M)	(3.7M)	(6.2M)	(12.0M)	(13.8M)	(13.1M)
Cash	7.9M	10.2M	5.8M	978.7K	1.1M	1.1M
Non Current Assets Total	28.2M	28.2M	30.9M	32.3M	37.2M	39.0M
Non Currrent Assets Other	26.2K	26.1K	76.6K	57.7K	51.9K	49.3K
Cash And Short Term Investments	7.9M	10.2M	5.8M	978.7K	1.1M	1.1M
Net Receivables	1.9M	2.7M	1.8M	2.2M	2.5M	2.6M
Common Stock Shares Outstanding	7.2M	7.6M	7.7M	7.7M	8.9M	9.4M
Liabilities And Stockholders Equity	40.4M	44.5M	44.9M	43.8M	50.4M	52.9M
Non Current Liabilities Total	9.9M	9.4M	11.4M	14.6M	16.8M	15.2M
Inventory	2.1M	3.1M	6.0M	7.8M	9.0M	9.4M
Other Current Assets	253.6K	268.7K	363.9K	493.9K	444.5K	247.6K
Other Stockholder Equity	31.2M	35.5M	35.8M	36.2M	41.7M	43.7M
Total Liab	12.1M	11.9M	14.5M	18.8M	21.6M	22.7M
Total Current Assets	12.2M	16.3M	14.0M	11.5M	13.2M	7.0M
Short Term Debt	860.8K	920.2K	1.1M	2.1M	1.9M	1.8M
Intangible Assets	95.5K	76.4K	57.3K	38.2K	34.4K	32.7K
Accounts Payable	602.3K	745.0K	790.0K	874.6K	1.0M	1.1M
Property Plant And Equipment Gross	25.3M	26.8M	42.0M	46.5M	53.5M	56.2M
Other Assets	406.0	312.0	351.0	1.0	0.9	0.86
Long Term Debt	7.1M	8.7M	8.3M	9.2M	10.6M	11.1M
Property Plant Equipment	25.3M	28.0M	28.0M	30.6B	35.2B	37.0B
Net Tangible Assets	28.8M	27.8M	32.3M	30.2B	34.8B	36.5B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

When determining whether ImmuCell offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ImmuCell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immucell Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immucell Stock:

How To Invest In ImmuCell

Details

Is ImmuCell Stock a good investment?

Details

What is ImmuCell's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.

You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmuCell. If investors know ImmuCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmuCell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.63)

Earnings Share

(0.49)

Revenue Per Share

2.991

Quarterly Revenue Growth

0.549

Return On Assets

(0.05)

The market value of ImmuCell is measured differently than its book value, which is the value of ImmuCell that is recorded on the company's balance sheet. Investors also form their own opinion of ImmuCell's value that differs from its market value or its book value, called intrinsic value, which is ImmuCell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmuCell's market value can be influenced by many factors that don't directly affect ImmuCell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmuCell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ImmuCell Historical Balance Sheet

ImmuCell Inventory

9.43 Million

About ImmuCell Balance Sheet Analysis

ImmuCell Balance Sheet Chart

Total Assets

Total Current Liabilities

ImmuCell balance sheet Correlations

ImmuCell Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ImmuCell balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Other Stockholder Equity	+ 1.0	Common Stock Shares Outstanding
Common Stock	+ 1.0	Common Stock Total Equity
Property Plant And Equipment Net	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Total Assets

Inventory	- 0.93	Retained Earnings
Retained Earnings	- 0.93	Other Current Liab
Retained Earnings	- 0.89	Net Debt
Short Term Debt	- 0.86	Retained Earnings
Retained Earnings	- 0.86	Total Current Liabilities
Retained Earnings	- 0.86	Short Long Term Debt Total